These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 36737060)

  • 41. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
    Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.
    Fan L; Wang L; Cao L; Zhu H; Xu W; Li J
    Front Med; 2022 Apr; 16(2):285-294. PubMed ID: 34727319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel.
    Cutini I; Puccini B; Fabbri A; Santi R; Gozzini A; Nozzoli C; Boncompagni R; Innocenti C; Saccardi R
    Transpl Immunol; 2022 Dec; 75():101719. PubMed ID: 36116729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
    Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
    Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
    Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
    Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 50. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data.
    Messori A; Chiumente M; Mengato D
    Clin Ther; 2022 Dec; 44(12):1626-1632. PubMed ID: 36503735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD19-directed CAR T-cell therapy in B-cell NHL.
    Kersten MJ; Spanjaart AM; Thieblemont C
    Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
    Myers GD; Verneris MR; Goy A; Maziarz RT
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33846220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
    Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?
    Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
    J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
    Ababneh HS; Ng AK; Frigault MJ; Abramson JS; Johnson PC; Jacobson CA; Patel CG
    Haematologica; 2023 Nov; 108(11):2972-2981. PubMed ID: 37317884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
    Scholler N; Perbost R; Locke FL; Jain MD; Turcan S; Danan C; Chang EC; Neelapu SS; Miklos DB; Jacobson CA; Lekakis LJ; Lin Y; Ghobadi A; Kim JJ; Chou J; Plaks V; Wang Z; Xue A; Mattie M; Rossi JM; Bot A; Galon J
    Nat Med; 2022 Sep; 28(9):1872-1882. PubMed ID: 36038629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
    Frank MJ; Baird JH; Kramer AM; Srinagesh HK; Patel S; Brown AK; Oak JS; Younes SF; Natkunam Y; Hamilton MP; Su YJ; Agarwal N; Chinnasamy H; Egeler E; Mavroukakis S; Feldman SA; Sahaf B; Mackall CL; Muffly L; Miklos DB;
    Lancet; 2024 Jul; 404(10450):353-363. PubMed ID: 38996463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.